WebinarsNew
Deep DiveNew
Explore Business Standard
The Central Board of Indirect Taxes and Customs (CBIC) has issued a standardised checklist which a Customs officers will have to follow before clearing import consignments of cosmetics, drugs and medical devices. These products require certain mandatory compliance in terms of licenses, permissions, and registration certificates, as per the provisions of the Drugs and Cosmetics Act, 1940. The checklist follows the Central Drugs Standard Control Organisation (CDSCO)'s measures to facilitate and enhance ease of doing business in these products, the CBIC circular said. These products have been grouped into seven categories -- cosmetics; Drugs in the form of API, finished formulation, import for personal use/import of small quantities of new drug by a medical institution, import for test/analysis. The checklist for medical devices import has been grouped into in vitro diagnostics kits/devices, import of medical devices and import of raw material for manufacture of such devices. "... Th
The Union Health Ministry has published a draft notification proposing amendments to the drugs rules under which imported drugs should have a minimum residual shelf life of 12 months at the time of import. The step would ensure that patients receive medicines with adequate usable shelf life and improve utilisation of pharmaceutical inventories across the supply chain. The draft amendment published for public consultation vide gazette notification on June 22 proposes to revise the existing requirement of a minimum residual shelf life of more than 60 per cent for imported drugs to a minimum residual shelf life of 12 months at the time of import. However, in view of their specialised nature and public health considerations, the existing requirement of a minimum residual shelf life of more than 60 per cent shall continue to apply to biological products and radiopharmaceuticals. The proposed amendment seeks to facilitate greater efficiency in the pharmaceutical supply chain while ...
The government has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs, an official statement said on Monday. The Department of Pharmaceuticals had launched the PLI scheme for promotion of domestic manufacturing of critical bulk drugs -- Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs). It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30. All the 215 applications received for the 36 products spread across the four target segments were considered and appraised and selected participants duly informed, the Ministry of Chemicals and Fertilizers said. Now, four waitlisted applicants who are otherwise eligible have been approved against slots vacated by withdrawal by companies which had earlier been granted approvals, the ministry said. The companies which have been gi